Business context and reporting period
Filing identity differs from request: the supplied 10-K is for Vallon Pharmaceuticals, Inc. (Nasdaq: VLON), not GRI Bio, Inc. It reports the fiscal year ended December 31, 2021; it does not provide a separate 2021 fourth-quarter financial presentation.
Vallon is a clinical-stage biopharmaceutical company developing abuse-deterrent CNS medications. Its lead candidate, ADAIR, is an immediate-release dextroamphetamine formulation for ADHD and narcolepsy; ADMIR, an abuse-deterrent methylphenidate formulation, was in earlier development. Neither candidate was approved or generating product sales.
Financial results and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $0 | $100,000 |
| Research and development | $5.187 million | $3.707 million |
| General and administrative | $4.072 million | $1.181 million |
| Operating loss | $9.259 million | $4.788 million |
| Net loss | $9.303 million | $4.822 million |
| Net loss per share | $1.42 | $1.07 |
| Cash used in operating activities | $8.312 million | $3.706 million |
Revenue in 2020 was the upfront payment under the related-party Medice license; no licensing revenue was recognized in 2021. With no product sales, margins are not meaningful. R&D rose $1.5 million, mainly due to ADAIR registration-development work; G&A rose $2.9 million, including higher directors’ and officers’ insurance, personnel and public-company costs.
At year-end, cash and cash equivalents were $3.702 million and available-for-sale marketable securities were $3.808 million, or $7.510 million combined. Current assets were $8.129 million versus current liabilities of $2.445 million. Total liabilities were $2.517 million; finance-lease liabilities were $169,000, and the balance sheet showed no note payable. Accumulated deficit was $21.902 million. Operating cash use increased from the prior year; investing cash use was $3.842 million, principally for marketable securities, while financing provided $15.747 million, primarily from the IPO and convertible-note financing.
Material changes and notable items
- Vallon completed a February 2021 IPO of 2.25 million shares at $8.00 per share, receiving approximately $15.5 million net proceeds. The $350,000 convertible notes converted into 54,906 shares at the IPO.
- The company reported that year-end cash and securities were expected to fund operations only into the third quarter of 2022. The auditor’s report includes a going-concern explanatory paragraph, citing substantial doubt about Vallon’s ability to continue as a going concern.
- In January 2021, the $61,000 Paycheck Protection Program note was forgiven and recorded as other income. A $89,000 change in fair value of the convertible-note derivative was also recorded in 2021.
- Management said disclosure controls and internal control over financial reporting were effective at December 31, 2021. Prior-period material weaknesses related to segregation of duties, accounting documentation and transaction controls were reported as remediated; the auditor did not attest to internal-control effectiveness.
Outlook, risks and contingencies
The SEAL pivotal intranasal abuse study had completed enrollment and treatment; 55 subjects enrolled after qualification and 53 completed. Management expected top-line results in the first quarter of 2022. The company continued ADAIR preclinical and manufacturing work and was evaluating studies needed for an FDA NDA. Management stated that substantial additional financing would be required; without it, Vallon could reduce or discontinue operations. No assurance was given that financing would be available or that development would succeed.
Medice holds an exclusive European ADAIR license and is responsible for seeking European regulatory approval. Vallon may receive up to $6.3 million in regulatory and sales milestones and tiered royalties of 10%–20% on net sales. Medice is affiliated with a principal stockholder and has board representation, making the relationship a related-party arrangement.
Principal risks include clinical and regulatory failure or delay, the FDA’s acceptance of the 505(b)(2) pathway and abuse-deterrence labeling, dependence on limited third-party manufacturers and clinical contractors, controlled-substance restrictions, competition, and the need for further capital. COVID-19 could disrupt trials, suppliers and regulatory activity. The company disclosed an accessibility class action settled for an immaterial amount; it reported no material legal proceedings elsewhere in the filing.
Important facts for investors to verify
- Confirm the issuer: this document is Vallon Pharmaceuticals (VLON), not GRI Bio, and confirm whether a different filing was intended.
- Check subsequent filings for actual ADAIR SEAL results, FDA feedback, NDA plans and any change in development status.
- Review subsequent cash balances, financing, burn rate and going-concern disclosures against the stated runway into Q3 2022.
- Verify whether Medice advanced European development and whether any license milestones or royalties were earned.
- Assess financing-related dilution, manufacturing arrangements, and the risks to ADAIR’s regulatory pathway and abuse-deterrent claims.